Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19

BACKGROUND: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication in vitro. MATERIALS & METHODS: Adults in hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study amended to two parts after interim analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Horga, Arantxa, Kuritzkes, Daniel R., Kowalczyk, John J., Pietropaolo, Keith, Belanger, Bruce, Lin, Kai, Perkins, Kristen, Hammond, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308776/
http://dx.doi.org/10.2217/fvl-2023-0064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308776/
http://dx.doi.org/10.2217/fvl-2023-0064

Ejemplares similares